An evidence‐based clinical guideline for the diagnosis and management of Paget's disease
of bone (PDB) was developed using GRADE methodology, by a Guideline Development …

Calcitonin (CT), a 32 amino acid peptide hormone produced primarily by the thyroid, and its
receptor (CTR) are well known for their ability to regulate osteoclast mediated bone …

Studies of the mode of action of the bisphosphonate alendronate showed that 1 d after the
injection of 0.4 mg/kg [3H] alendronate to newborn rats, 72% of the osteoclastic surface, 2 …

Bisphosphonates inhibit bone resorption in vivo and in vitro by unknown mechanisms. The
effect of bisphosphonates on the formation of osteoclasts from their mononuclear …

Three new bisphosphonates of various chain length, namely, 4-amino-1-hydroxybutylidene-
1, 1-bisphosphonate (AHBuBP), 5-amino-1-hydroxypentylidene-1, 1-bisphosphonate …

The cause of Paget's disease of bone (PDB) is unknown. In an attempt to ascertain the
proportion of familial cases and evaluate the influence of genetic factors on the occurrence …

Background Paget's disease is a disorder in which there is a marked increase in bone
turnover in localized parts of the skeleton. This results in an abnormal bone leading to …

Background Some people believe that patients who take part in randomised controlled trials
(RCTs) face risks that they would not face if they opted for non‐trial treatment. Others think …

PURPOSE: The potent bisphosphonates offer great promise in the management of Paget's
disease of bone, but are currently available only as parenteral preparations in most …

PURPOSE: To compare the efficacy and tolerability of oral risedronate and etidronate for
treatment of Paget's disease of bone. PATIENTS AND METHODS: Patients from 12 centers …